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BASIC STUDY

Efficacy and Safety of Pembrolizumab in Patients Enrolled in
KEYNOTE-030 in the United States: An Expanded Access
Program
Tara C. Gangadhar,* Wen-Jen Hwu,† Michael A. Postow,‡§ Omid Hamid,∥
Adil Daud,¶ Roxana Dronca,# Richard Joseph,** Steven J. O’Day,††
F.S. Hodi,‡‡ Anna C. Pavlick,§§ Harriet Kluger,∥∥ Romina P. Oxborough,¶¶
Aiming Yang,## Mihaela Gazdoiu,## Debra A. Kush,##
Scot Ebbinghaus,## and April K.S. Salama***

Summary: KEYNOTE-030 (ClinicalTrials.gov ID, NCT02083484)
was a global expanded access program that allowed access to pembrolizumab, an antiprogrammed death 1 antibody, for patients with
advanced melanoma before its regulatory approval. Patients with
unresectable stage III/IV melanoma that progressed after standard-ofcare therapy, including ipilimumab and, if BRAFV600 mutant, a
BRAF inhibitor, were eligible to receive pembrolizumab 2 mg/kg
every 3 weeks. Response was assessed by immune-related response
criteria by investigator review. Adverse events (AEs) were graded
according to the National Cancer Institute Common Terminology
Criteria for Adverse Events, version 4.0. In the United States, 979
patients enrolled between April and September 2014. Of the 947
evaluable patients, 621 (65.6%) remained on treatment and transitioned to receive commercial pembrolizumab following approval by
the Food and Drug Administration, whereas 326 (34.4%) discontinued, most commonly for disease progression (39.6%) or death
(26.4%). Objective response rate was 14.5% (95% conﬁdence interval,
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12.2%–16.8%) in the treated population (n = 947) and 22.1% (95%
conﬁdence interval, 18.8%–25.5%) in patients who had ≥ 1 response
assessment reported (n = 619). Twelve patients achieved complete
response. One hundred eighty-one (19.1%) patients experienced ≥ 1
treatment-related AE, most commonly general disorders (8.0%), skin/
subcutaneous tissue disorders (7.3%), and gastrointestinal disorders
(6.4%); 29 (3.1%) patients experienced ≥ 1 grade 3/4 treatment-related
AE. Immune-mediated AEs were also reported. There were no
treatment-related deaths. The safety and efﬁcacy observed in this
expanded access program were consistent with those previously
reported for similar populations and support the use of pembrolizumab for patients with advanced melanoma.
Key Words: expanded access program, immunotherapy, melanoma,
PD-1, pembrolizumab

(J Immunother 2017;40:334–340)

M

elanoma incidence continues to rise both in the United
States and globally, with 87,110 new cases and 9730
related deaths estimated in 2017 in the United States alone.1
The prognosis for patients with advanced disease has been
historically poor; however, advances in immunotherapy as a
therapeutic option for many tumors, including melanoma,
have improved outcomes for this patient population.
Immune checkpoints are costimulatory or coinhibitory
signals that maintain self-tolerance and limit collateral tissue
damage during an immune response.2,3 Cytotoxic T-lymphocyte–associated antigen 4 is a coinhibitory molecule that
inhibits T-cell proliferation.4–6 Another immune checkpoint,
programmed death 1 (PD-1), acts within the tumor
microenvironment to negatively regulate T-cell response at
the effector stage.4,7 Tumors are able to co-opt immune
checkpoint pathways to evade an antitumor immune
response;4,8,9 thus, checkpoint blockade is an effective strategy
for treating many tumors, including melanoma. The anticytotoxic T-lymphocyte–associated antigen 4 antibody ipilimumab was the ﬁrst checkpoint inhibitor approved for the
treatment of advanced melanoma in 2011 and was the ﬁrst
drug to demonstrate improved survival for this patient
population.10,11 More recently, the PD-1–blocking drugs
pembrolizumab12–15 and nivolumab16–19 have further
improved outcomes in patients with metastatic melanoma.
The anti-PD-1 humanized monoclonal antibody pembrolizumab has demonstrated efﬁcacy and manageable toxicity in patients with advanced melanoma enrolled in 3 large
clinical trials. In the phase IKEYNOTE-001 study (ClinicalTrials.gov ID, NCT01295827; n = 655), pembrolizumab
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demonstrated durable antitumor activity and a manageable
safety proﬁle in patients with ipilimumab-naive and ipilimumab-treated advanced melanoma.13 In the phase II KEYNOTE-002 study (ClinicalTrials.gov ID, NCT01704287;
n = 540), pembrolizumab demonstrated superior progressionfree survival and objective response rate (ORR) and had less
high-grade toxicity compared with investigator-choice chemotherapy in patients with ipilimumab-treated advanced
melanoma.20 In addition, in the phase III randomized KEYNOTE-006 study (ClinicalTrials.gov, NCT01866319;
n = 834), pembrolizumab demonstrated superior overall survival, progression-free survival, and ORR, and less high-grade
toxicity, compared with ipilimumab in patients with ipilimumab-naive advanced melanoma who received ≤ 1 prior
therapy.21 Pembrolizumab is currently approved in more than
60 countries for 1 or more advanced malignancies, including
unresectable or metastatic melanoma based on the results of
the aforementioned studies, and is being evaluated in > 30
additional solid tumors and hematologic malignancies.
KEYNOTE-030 (ClinicalTrials.gov, NCT02083484), the
pembrolizumab multisite global expanded access program
(EAP), was initiated in April 2014 based on the key melanoma
clinical data described above to address the unmet medical
need for patients with metastatic melanoma whose disease
progressed on prior systemic treatments or for whom limited
or no treatment options existed. The EAP was not designed
as a clinical trial, but rather as a streamlined approach to
provide patients who had no other therapeutic options access
to pembrolizumab during the time between completion of
enrollment of pembrolizumab clinical trials and its regulatory
approval. As such, data collection and formal analyses were
limited in scope. Here, we report the results for the cohort of
patients enrolled in the EAP from the United States.

MATERIALS AND METHODS
Patients

Eligibility criteria for the EAP included age ≥ 12 years;
unresectable (stage III) or metastatic (stage IV) melanoma
with progression on standard systemic therapy including
ipilimumab, and when indicated, a BRAF/MEK inhibitor;
Eastern Cooperative Oncology Group performance status 0
or 1; adequate organ function; and provision of written
informed consent. Patients were excluded if they had participated in or were eligible for a pembrolizumab clinical
trial or for treatment with an approved BRAF/MEK
inhibitor. Additional exclusion criteria included unresolved
adverse events (AEs) from prior therapy; active central
nervous system metastases (patients with previously treated
brain metastases were eligible provided they were clinically
stable as assessed by the treating physician); or history of
pneumonitis, organ transplant, human immunodeﬁciency
virus infection, active infection with hepatitis B or hepatitis
C virus, or autoimmune disease requiring long-term
immunosuppressive therapy. The EAP enrolled approximately 5800 patients worldwide.

Treatment and Assessments
Eligible patients received intravenous pembrolizumab
2 mg/kg every 3 weeks; treatment continued for 24 months
or until conﬁrmed disease progression per immune-related
response criteria (irRC),22 unacceptable toxicity, conﬁrmed
positive pregnancy test, withdrawal of consent, physician
decision, or approval of pembrolizumab in the country of
treatment, whichever occurred ﬁrst. The planned end of
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enrollment was designated as the time at which pembrolizumab became commercially available following regulatory approval. Patients enrolled at the time of approval
could receive up to 2 additional treatment cycles through the
EAP while transitioning to treatment with commercial
pembrolizumab.
Per protocol, and similar to some other EAPs, extensive
data collection and analyses were not required for this program. Clinical assessments were performed according to the
standard of care at the treating institution or center. Tumor
response was assessed per irRC by investigator review. Laboratory safety assessments were performed locally before the
ﬁrst pembrolizumab dose and before each treatment cycle
thereafter. AEs were collected continuously until treatment
discontinuation and graded according to the National Cancer
Institute Common Terminology Criteria for Adverse Events,
version 4.0. Prespeciﬁed immune-mediated AEs and serious
AEs were reported within 24 hours. Treatment-related nonserious AEs were reported within 5 days.
Pembrolizumab was withheld for grade > 2 treatmentrelated nonhematologic AEs (excluding fatigue). Upon
recovery of the event to grade 0–1, dose modiﬁcation (ie,
increasing the dosing interval in subsequent cycles to 4 wk)
was permitted. Treatment discontinuation was recommended for treatment-related AEs that did not resolve to
grade 0–1 within 12 weeks after onset of the AE and for
treatment-related severe or life-threatening AEs. Immunemediated AEs were managed with the use of corticosteroids;
discontinuation was recommended for grade 2 treatmentrelated AEs thought to be immune-mediated that persisted
without improvement for > 4 weeks and for the inability to
reduce corticosteroid dose for the management of such AEs
to the equivalent of ≤ 10 mg of prednisone daily. Additional
information regarding the management of immune-mediated AEs was provided to all sites in the form of an Event
of Clinical Interest and Immune-related Adverse Event
Guidance Document.

Program Oversight
The EAP was conducted in accordance with the protocol, good clinical practice standards, and the Declaration
of Helsinki. The protocol and all amendments were
approved by the relevant institutional review boards or
independent ethics committees at all participating sites in
the United States. All patients provided written informed
consent. Patient data and trial operations were monitored
by the program sponsor through remote data monitors who
were in contact with the sites.

Statistical Analysis
Efﬁcacy and safety were evaluated in all enrolled
patients who received ≥ 1 dose of pembrolizumab. Efﬁcacy
was also reported in the subset of patients with ≥ 1 postbaseline tumor assessment because tumor assessments were
limited in the full treatment population by those patients
who transitioned to commercial pembrolizumab before they
had any response assessment. Patient demographics were
reported using descriptive statistics. The ORR was calculated and reported as the number of complete or partial
responses per irRC by investigator review, divided by the
total number of evaluable patients in the efﬁcacy population. Safety data were summarized using frequencies and
percentages. The data cutoff for analysis was March 31,
2015. Data were not collected once patients transitioned to
commercial pembrolizumab.

Copyright r 2017 The Author(s). Published by Wolters Kluwer Health, Inc.
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TABLE 1. Baseline Demographics and Disease Characteristics
of the Treated Population

Patients
A total of 979 patients from 90 sites in the United
States provided informed consent between April and September 2014 (Fig. 1). Of these, 947 patients received ≥ 1
dose of pembrolizumab (Fig. 1) and were included in the
efﬁcacy and safety analyses. Baseline patient characteristics
were as expected for an advanced melanoma population
with progression after ipilimumab and, if eligible, a BRAF/
MEK inhibitor (Table 1). Median patient age was 61 years
(range, 15–94 y), 66.0% were male, 57.9% had an Eastern
Cooperative Oncology Group performance status of 0, and
95.7% had stage IV disease.
The program was closed to enrollment in the United
States as of September 4, 2014, the date of pembrolizumab
approval by the Food and Drug Administration. At the time
of completion of enrollment, the median duration of pembrolizumab treatment was 64 days (range, 1–190 d), and 621
(65.6%) patients remained on treatment and transitioned to
receive commercial pembrolizumab (Fig. 1). The remaining
326 (34.4%) patients discontinued pembrolizumab treatment
before enrollment was complete; the most common reasons
for discontinuation were radiographic disease progression
(39.6%) and death (26.4%; Fig. 1). Additional reported
reasons for discontinuing pembrolizumab treatment before
completion of enrollment were withdrawal of consent
(7.4%), toxicity (5.2%), other reasons [18.1%; includes clinical progression, transfer of care, decline in performance
status, investigator decision, lost to follow-up, brain metastases, progressive disease per positron-emission tomography, complete response, lack of response, treatment for a
secondary malignancy (myelodysplastic syndrome in 1
patient)], and reason not speciﬁed (3.4%).

Efficacy
The ORR per irRC by investigator assessment was
14.5% (95% conﬁdence interval, 12.2%–16.8%) in the entire

Characteristic
Age, median (range), y
Male, n (%)
Weight, mean (SD), kg
ECOG performance status, n (%)
0
1
2
Disease stage, n (%)
III
IV
Prior PD-1/PD-L1–based therapy, n (%)
Other anti–PD-1 monoclonal antibody
Anti–PD-L1 antibody

N = 947
61 (15–94)
625 (66.0)
81.2 (19.1)
548 (57.9)
398 (42.0)
1 (0.1)
41 (4.3)
906 (95.7)
28 (3.0)
11 (1.2)

ECOG indicates Eastern Cooperative Oncology Group; PD-1, programmed death 1; PD-L1, programmed death ligand 1; SD, standard
deviation.

treated population of 947 patients (regardless of whether
response data were reported) and was 22.1% (95% conﬁdence interval, 18.8%–25.5%) in the 619 patients who had
≥ 1 response assessment reported while enrolled in the program (Table 2). Best overall response in the 619 patients
who had ≥ 1 response assessment was complete response in
12 (1.9%) patients and partial response in 125 (20.2%)
patients; an additional 203 (32.8%) patients achieved stable
disease (Table 2).

Safety

A total of 400 (42.2%) patients experienced ≥ 1 AE,
regardless of grade or attribution to study treatment; treatment-related AEs were reported in 181 (19.1%) patients
(Table 3). The most frequently reported treatment-related
AEs of any grade fell under the system organ class

Patients Enrolled
N = 979

Received ≥1 pembrolizumab dose
N = 947

Discontinued pembrolizumab
n = 326

On treatment at program closure
n = 621

• Disease progression (n = 129)
• Death (n = 86)
• Withdrawal of consent (n = 24)†
• Toxicity (n = 17)
• Other (n = 59)‡
• Not specified (n = 11)

Transferred to commercial supply
n = 621

FIGURE 1. Patient disposition; †one patient who experienced a complete response and 2 patients who experienced a partial response;
‡clinical progression (n = 20), transfer of care (n = 15), decline in performance status (n = 7), investigator decision (n = 3), lost to followup (n = 3), brain metastases (n = 2), progressive disease per positron-emission tomography (n = 2), complete response (n = 1), lack of
response (n = 1), and treatment for a secondary malignancy [myelodysplastic syndrome (n = 1)].
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TABLE 2. Best Overall Response per irRC by Investigator Assessment

ORR, % (95% CI)
DCR, % (95% CI)
Best overall response, %
Complete response
Partial response
Stable disease
Progressive disease
Not assessed
Unknown

n

Treated Population
N = 947

Patients With ≥ 1
Response Assessment
N = 619

137
340

14.5 (12.2–16.8)
35.9 (32.8–39.0)

22.1 (18.8–25.5)
54.9 (50.9–58.9)

12
125
203
279
324
4

1.3
13.2
21.4
29.5
34.2
0.4

1.9
20.2
32.8
45.0
—
—

CI indicates conﬁdence interval; DCR, disease control rate; irRC, immune-related response criteria;
ORR, objective response rate.

categories of general disorders and administration site conditions (included fatigue; 8.0%), skin and subcutaneous tissue disorders (7.3%), and gastrointestinal disorders (6.4%;
Fig. 2). A total of 29 (3.1%) patients experienced ≥ 1 grade
3–4 treatment-related AE (Table 3). The most common
possibly immune-mediated AEs were rash (4.3%) and pruritus
(4.4%; Table 4). There were no treatment-related deaths
reported (Table 3), and only 17 (1.8%) patients discontinued
therapy because of treatment-related toxicity (Fig. 1).

DISCUSSION
In 3 key clinical trials,13,20,21 pembrolizumab demonstrated a favorable risk/beneﬁt proﬁle in both previously
treated and treatment-naive patients with advanced melanoma. The KEYNOTE-030 global EAP for patients with
stage III or IV melanoma whose disease progressed on ipilimumab and a BRAF/MEK inhibitor (when indicated) was
designed to ﬁll an unmet treatment need during the time
between the completion of enrollment of pembrolizumab
clinical trials and its commercial availability for those
patients without other therapeutic options.
The 22.1% ORR observed in the 619 patients who had
≥ 1 response assessment was slightly lower than expected
compared with clinical trials of pembrolizumab in mixed
patient populations. In the KEYNOTE-001 trial, ORR as
assessed per Response Evaluation Criteria In Solid Tumors,
version 1.1 (RECIST v1.1) by central imaging vendor
review was reported as 33% in the overall population, 29%
among ipilimumab-treated patients, and up to 45% in the
subset of treatment-naive patients.13 More recently, the
TABLE 3. Summary of AEs in Patients Who Received ≥ 1 Dose
of Pembrolizumab
Patients With ≥ 1 AE, n (%)
N = 947

AE
Any attribution, any grade
Treatment related, any grade
Treatment related, grade 3–4
Treatment-related deaths
Serious
Treatment-related, serious
Leading to dose interruption
AE indicates adverse event.

400
181
29
0
240
32
44

(42.2)
(19.1)
(3.1)
(0)
(25.3)
(3.4)
(4.6)

ORR in the KEYNOTE-006 trial was reported as 33%–
34%, depending on pembrolizumab dosing regimen, in
patients who were ipilimumab naive.21 The patient populations in the KEYNOTE-001 and KEYNOTE-006 trials,
however, were not closely matched to that of the EAP,
whereas the KEYNOTE-002 trial included eligibility criteria
similar to those of the EAP (eg, stage III or IV melanoma
and previous treatment with ipilimumab and a BRAF
inhibitor if BRAFV600 mutant). Although data on M substage were not collected for this EAP, we would expect a
distribution similar to that of KEYNOTE-002, in which the
majority of patients (82%–83%) treated with pembrolizumab had stage M1c disease.20 Accordingly, the ORR
in KEYNOTE-002 was comparable to that observed in the
EAP (21%–25% for the 2 pembrolizumab dose cohorts
studied).20 Similar response rates have been reported for
nivolumab, also in varying patient populations.16–19
Differences in ORR may be attributable to slight differences in the patient populations. Of note, unlike the clinical trials of pembrolizumab, this program included patients
with uveal or mucosal melanoma, who may have lower
response rates than patients with primary cutaneous
melanoma.23,24 Although published data are limited on
patients with uveal or mucosal melanoma treated with
immunotherapies, lower rates of response for these populations are typically reported. Recent studies report an ORR
of 0%–4% in patients with uveal melanoma23,25,26 and of
19%–23% in patients with mucosal melanoma.27,28 It is
interesting to note that, in published case reports of a small
subset of patients with uveal melanoma from this EAP, ORR
was higher (37.5%) than in the overall population;29 however,
an additional 3 patients, at least 1 of whom had a partial
response, received commercial pembrolizumab outside of the
EAP and were included in this response assessment, which
might have contributed to the discrepancy in response rates
between the case studies and the data reported here.29 In
addition, post hoc analyses of outcomes in KEYNOTE-00130
and KEYNOTE-00631 found that patients with elevated
lactate dehydrogenase (LDH) levels ( > 1× the upper limit of
normal) had a lower ORR than patients with normal LDH
levels. Although data on LDH level were not collected for the
EAP, we would expect the distribution of LDH to be similar
to that of KEYNOTE-002, in which 55%–58% of patients
had normal LDH levels and 40%–43% had elevated LDH
levels.20 Thus, inclusion of patient populations with uveal or
mucosal melanoma and elevated LDH levels might have
contributed to a lower overall ORR in this program.

Copyright r 2017 The Author(s). Published by Wolters Kluwer Health, Inc.

www.immunotherapy-journal.com

| 337

J Immunother

Gangadhar et al



Volume 40, Number 9, November/December 2017

8.0

General disorders and administration site conditions†
Skin and subcutaneous tissue disorders
Gastrointestinal disorders
Investigations
Musculoskeletal disorders
Metabolism and nutrition disorders
Endocrine disorders
Nervous system disorders
Respiratory, thoracic and mediastinal disorders
Blood and lymphatic system disorders
Vascular disorders
Infections and infestations
Neoplasms benign, malignant and unspecified
Eye disorders
Hepatobiliary disorders
Immune system disorders
Injury, poisoning and procedural complications
Psychiatric disorders
Renal and urinary disorders

7.3
6.4
3.4
2.7
2.5
1.8
1.6
1.4
1.0
0.4
0.3
0.3
0.2
0.1
0.1
0.1
0.1
0.1

0

1

2

3

4

5

6

7

8

9

10

Patients, %

FIGURE 2. Incidence of treatment-related adverse events of any grade by system organ class. Patients could have experienced > 1
treatment-related adverse event in > 1 system organ class. There were no cardiac disorders, reproductive system and breast disorders, or
surgical and medical procedures that were considered to be treatment related; †fatigue.

The use of different response criteria, including the use
of unconﬁrmed response by investigator assessment in the
EAP, might also have contributed to differences in response
rates between the EAP and clinical trials. Unlike irRC,
conventional response criteria, such as RECIST v1.1, do not
consider the fact that disease stabilization can occur after an
initial increase in tumor burden, so response rates are typically lower than with irRC. Previous studies in melanoma
have demonstrated that atypical response patterns (eg, disease stabilization after initial evidence of disease progression) were observed in 7% of patients treated with
pembrolizumab32 and in 10% of patients treated with
ipilimumab22 using irRC. However, in the EAP, response
data were not submitted for all 947 evaluable patients
because many of them (34.6%) had not yet reached their ﬁrst
response assessment when they transitioned to commercial
drug supply at the time of program closure, and, as such,
more patients with response might have been reported as

TABLE 4. AEs of Interest Based on Possible Immune Etiology

AE

Patients With Event, n (%)
N = 947

Rash and/or pruritus
Rash*
Pruritus
Endocrinopathy
Hypothyroidism
Adrenal insufﬁciency
Hypophysitis
Hyperthyroidism
Hypopituitarism
Arthralgia
Vitiligo or skin hypopigmentation

83
41
42
21
9
7
2
2
1
17
8

(8.8)
(4.3)
(4.4)
(2.2)
(1.0)
(0.7)
(0.2)
(0.2)
(0.1)
(1.8)
(0.8)

AEs were considered regardless of attribution to treatment by the
investigator or grade of severity.
*Includes rash, rash erythematous, and rash maculopapular.
AE indicates adverse event; ORR, objective response rate.

338 | www.immunotherapy-journal.com

having had clinical progression. Furthermore, responses to
pembrolizumab are generally durable, as demonstrated in
KEYNOTE-00133 and KEYNOTE-006,34 in which 97%
and 93% of responses, respectively, were ongoing with
3 years of follow-up; we would therefore expect a similar
outcome with the EAP if patients had continued the program. Thus, the results reported here must be interpreted
within the context of the short treatment duration and follow-up times of the EAP because the potential for capturing
atypical and durable responses was limited. Despite these
differences, the response rate in the EAP is reassuringly
similar to the response rates reported in the pembrolizumab
clinical trial program.
In this EAP, pembrolizumab was well tolerated in
patients with advanced melanoma whose disease progressed
after standard-of-care therapy, with an observed safety
proﬁle consistent with that reported for similar populations
in the KEYNOTE-001,13 KEYNOTE-002,20 and KEYNOTE-00621 studies. No new or unexpected AEs or treatment-related deaths were reported.
Similar to the pembrolizumab clinical trials, fatigue
was the most frequent AE observed in the EAP. The lower
rates of any grade (19.1%) and grade 3–4 (3.1%) treatmentrelated AEs reported in this EAP compared with the clinical
trials are likely related in part to decreased reporting
because the program was monitored remotely, with individual sites responsible for the collection and reporting of
AE data for their patients. Thus, nonserious AEs were likely
underreported. In addition, because this analysis included
all patients who were enrolled up until the designated program end at the time of regulatory approval and commercial
availability of pembrolizumab, median duration of treatment was only 64 days (range, 1–190 d) at the time of program closure. At this time, 621 (65.6%) patients remained
on treatment and transitioned to receive commercial pembrolizumab. Had the median duration of treatment and
follow-up period been longer for more patients, additional
AEs would likely have been reported, with expected frequencies closer to those reported in the clinical trials.
Therefore, the lower incidence of AEs reported here may be

Copyright r 2017 The Author(s). Published by Wolters Kluwer Health, Inc.
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attributed to the underreporting of nonserious AEs in
combination with the short follow-up times in the EAP.
This EAP was not designed to evaluate the feasibility
and outcomes of treating patients with poor performance
status, decreased organ function, uncontrolled brain metastases, or autoimmune disease with pembrolizumab; ongoing clinical trials will address PD-1 blockade in these subsets
of patients. Despite the limitations inherent in the EAP,
these data support the use of pembrolizumab for patients
with advanced melanoma outside of the clinical trial setting.
The administration of pembrolizumab was manageable
across the broad scope of clinical treatment practices
encompassed in this large EAP, demonstrating the feasibility of treating this population of patients in community
practice.
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